Trial Profile
Randomized Phase IB/II Study of Enzalutamide With and Without Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary) ; Enzalutamide
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Mar 2024 Status changed from active, no longer recruiting to completed.
- 23 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2023 Planned number of patients changed from 90 to 53.